Clin Infect Dis:南非晚期HIV疾病队列中抗体免疫与隐球菌抗原血症和死亡率的关系

2022-08-31 从医路漫漫 MedSci原创

HIV

在CD4计数<200个/mm3的个体中实施隐球菌抗原(CRAG)筛查,可以在症状出现之前识别出有可能发展为隐球菌性脑膜炎(CM)的HIV阳性个体,从而有助于更早的诊断检测和治疗。

背景:尽管国际上正在努力结束与隐球菌有关的死亡,但隐球菌病仍然是人类免疫缺陷病毒(艾滋病毒)携带者发病和死亡的主要原因。大多数病例发生在撒哈拉以南非洲,那里进行了大量研究工作,对隐球菌病进行了先进的治疗和预防。在CD4计数<200个/mm3的个体中实施隐球菌抗原(CRAG)筛查,可以在症状出现之前识别出有可能发展为隐球菌性脑膜炎(CM)的HIV阳性个体,从而有助于更早的诊断检测和治疗。

虽然通过CRAG筛查和先前的治疗计划,CM的发病率已经下降,但患有无症状隐球菌抗原血症的HIV阳性患者的死亡率仍然高于没有隐球菌抗原血症的人,即使在调整了CD4计数和先发制人的抗真菌治疗后也是如此。非CD4T细胞相关因素可能影响隐球菌病的发病机制,因为隐球菌病发生在CD4T细胞计数>200个/mm3的艾滋病毒阳性个体和艾滋病毒阴性个体中。以往的研究表明,在HIV感染者和非感染者中,新生隐球菌(CN)和β-葡聚糖(层粘素,一种分支的β-[1-3]-葡聚糖和柯德兰,一种线性的β-[1-3]-葡聚糖)结合抗体水平与CRAG或CM状态有关。

目的:在这项研究中,我们调查了有无无症状的隐球菌抗原血症的南非晚期HIV疾病患者的抗体免疫、隐球菌抗原血症和死亡率之间的关系。

方法:对197名南非HIV感染者的血液样本进行了隐球菌属荚膜葡糖醛酸木甘露聚糖(GXM)和天然β-葡聚糖(昆布多糖、凝胶多糖)结合抗体的检测,这些患者接受了CrAg筛查,并对其进行了为期6个月的前瞻性随访。分别使用logistic和Cox比例风险回归分析抗体滴度、CrAg状态和全因死亡率之间的关系。

结果:与CrAg阴性患者(n=130)相比,CrAg阳性患者(n=67)的IgG1水平明显较高(中位数,6,672[四分位间距,IQR,4,696-10,414]比5,343[3,808-7,722]mg/ml;P=0.007)、IgG 2(1467[813-2607]对1036[519-2,012]mg/ml;P=0.01)、GXM-IgG (1:170 [61-412]对1:117[47-176];P=0.0009)和较低的凝胶多糖-IgG (1:47 [11-133]对1:93[40-206]);P=0.01)滴度。GXM-IgG与隐球菌抗原血症直接相关,校正CD4计数和抗逆转录病毒治疗使用(优势比,滴度每对数增加1.64;95%可信区间[CI],1.21-2.22)。在CrAg阳性个体中,GXM-IgG与校正CD4计数和活动性或流行性结核后6个月的死亡率呈负相关(危险比为0.50;滴度每增加一个对数就降低两倍;95% CI,0.33-0.77)。

表1分层COX比例风险回归模型估计GXM-Ig G是登记后6个月死亡率的预测因子。

图1基线时130名CRAG阴性和67名CRAG阳性个体的总抗体水平和抗原特异性抗体水平。用Luminex和GXM测定总免疫球蛋白水平,用酶联免疫吸附试验测定海带多糖和可得兰抗体效价。免疫球蛋白浓度以mg/ml(A)为单位,GxM(B)、海带多糖(C)和可得兰(D)滴度的倒数,描绘为中间值和四分位数范围,在y轴上显示在x轴上的每一组。岩壁状态用(+)或(-)表示,分别表示正岩壁状态或负岩壁状态。*P<0.001;**P。Wilcoxon秩和检验。缩写:CRAG,隐球菌抗原;GXM,葡醛酸木甘露聚糖;Ig,免疫球蛋白。

图2单变量(A)和多变量(B)Logistic回归分析在130例CREG阴性和67例CRAG阳性的队列中估计抗体标记物和血浆CRAG状态之间的相关性。抗体变量采用对数变换。单变量分析中P<0.20的协变量被纳入多变量分析(CD4计数和ART使用)。结核病包括在登记前6个月内确诊的肺部、播散性或肺外感染。抗逆转录病毒药物的使用包括登记前的治疗史。P值<0.05以粗体显示。缩写:AOR,调整后的优势比;ART,抗逆转录病毒治疗;CI,可信区间;CRAG,隐球菌抗原;GXM,葡醛酸木甘露聚糖;OR,优势比。

图3。根据基线GXM-IgG分类的Kaplan-Meier生存曲线。GXM-IgG的反向滴度范围分为三等分;低(1.9-62.2),中(62.8-172.0),高GXM-IgG(176.3-3453.3)。显示了67名CrAg阳性个体(图A)和130名CrAg阴性个体(图B)的曲线。GXM-IgG在存活分析中被对数转换。缩写:GXM,葡糖醛酸木甘露聚糖。

结论:在RAG阳性患者中发现GXM-Ig G与死亡率呈负相关,提示GXM-Ig G滴度可能对此类患者有预后价值。对抗体水平进行前瞻性纵向研究,以调查这一假说,并确定抗体可预防死亡的机制是必要的。

原文出处: Yoon H,  Wake RM,  Nakouzi AS,et al.The association of antibody immunity with cryptococcal antigenemia and mortality in a South African cohort with advanced HIV disease.Clin Infect Dis 2022 Aug 02

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1414488, encodeId=9d5414144882f, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Wed Aug 31 12:24:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575819, encodeId=031315e5819a1, content=<a href='/topic/show?id=fb6a9853366' target=_blank style='color:#2F92EE;'>#隐球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98533, encryptionId=fb6a9853366, topicName=隐球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c26116195824, createdName=xugc, createdTime=Wed Aug 31 12:24:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623440, encodeId=c05e16234408f, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 31 12:24:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013952, encodeId=d0ee201395264, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Apr 24 10:24:08 CST 2023, time=2023-04-24, status=1, ipAttribution=)]
    2022-08-31 hongbochen
  2. [GetPortalCommentsPageByObjectIdResponse(id=1414488, encodeId=9d5414144882f, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Wed Aug 31 12:24:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575819, encodeId=031315e5819a1, content=<a href='/topic/show?id=fb6a9853366' target=_blank style='color:#2F92EE;'>#隐球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98533, encryptionId=fb6a9853366, topicName=隐球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c26116195824, createdName=xugc, createdTime=Wed Aug 31 12:24:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623440, encodeId=c05e16234408f, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 31 12:24:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013952, encodeId=d0ee201395264, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Apr 24 10:24:08 CST 2023, time=2023-04-24, status=1, ipAttribution=)]
    2022-08-31 xugc
  3. [GetPortalCommentsPageByObjectIdResponse(id=1414488, encodeId=9d5414144882f, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Wed Aug 31 12:24:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575819, encodeId=031315e5819a1, content=<a href='/topic/show?id=fb6a9853366' target=_blank style='color:#2F92EE;'>#隐球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98533, encryptionId=fb6a9853366, topicName=隐球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c26116195824, createdName=xugc, createdTime=Wed Aug 31 12:24:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623440, encodeId=c05e16234408f, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 31 12:24:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013952, encodeId=d0ee201395264, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Apr 24 10:24:08 CST 2023, time=2023-04-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1414488, encodeId=9d5414144882f, content=<a href='/topic/show?id=8e95364321f' target=_blank style='color:#2F92EE;'>#南非#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36432, encryptionId=8e95364321f, topicName=南非)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83403055912, createdName=hongbochen, createdTime=Wed Aug 31 12:24:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575819, encodeId=031315e5819a1, content=<a href='/topic/show?id=fb6a9853366' target=_blank style='color:#2F92EE;'>#隐球菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98533, encryptionId=fb6a9853366, topicName=隐球菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c26116195824, createdName=xugc, createdTime=Wed Aug 31 12:24:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623440, encodeId=c05e16234408f, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Aug 31 12:24:08 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013952, encodeId=d0ee201395264, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Apr 24 10:24:08 CST 2023, time=2023-04-24, status=1, ipAttribution=)]

相关资讯

JIAS:多替拉韦钠片抗逆转录病毒疗法在HIV和肺结核合并感染中的实际应用和结果

在全球范围内,HIV治疗计划正在从非核苷类逆转录酶抑制剂(NNRTIs) ,如依法韦仑,过渡到多替拉韦钠片,因为它具有更好的疗效和耐受性,以及对HIV耐药性的高遗传屏障。

Nature重磅:艾滋病治疗最新进展!新疗法有望长期控制病毒水平

为了减轻感染者的患病负担,一众科学家一直在探索可有效控制感染者体内病毒水平的疗法。如何研发出长期有效的艾滋病药物,成为诸多科学家的目标。

生物制剂治疗方案的安全管理:治疗前筛查与治疗后监测

很多患者小伙伴在打生物制剂前后会疑惑:使用生物制剂治疗前筛查哪些项目,打了生物制剂复诊随访又需要哪些项目?

CID:在急性HIV感染期间开始以EFV和DTG为基础的抗逆转录病毒治疗后的免疫、认知和精神预后

2018年,世界卫生组织(世卫组织)将其首选的治疗初治PLWH的一线抗逆转录病毒疗法从EFV改为DTG。

LCAH:母亲抗逆转录病毒治疗对未感染HIV的儿童早期神经发育的影响

据估计,全世界有1540万未感染艾滋病毒(HEU)的儿童,占一些艾滋病毒负担高的国家每年新生儿的20%以上。